Kinase 2021:

9th RSC / SCI symposium on kinase inhibitor design


Monday-Tuesday, 5th-6th July 2021

The Francis Crick Institute, London, UK



Registration is not yet open

(formerly planned for 1st-2nd June 2020)


Twitter hashtag - #Kinase21


Downloads and Links

Online registration - to pay by card

Registration form - for payment by bank transfer or cheque


Third announcement

Second announcement

First announcement

Poster abstract template - closing date is 21st May 2021

Bursary application form - closing date is 19th May 2021


Venue location weblink


Accommodation booking weblink - to be inserted


RSC website

SCI website


Coronavirus Disease (COVID-19)

Statement from RSC BMCS Committee

18th March 2020

With the ongoing Coronavirus situation and increasing requirements for social distancing, the RSC BMCS Committee has taken the decision to cancel all solely or jointly arranged meetings up to and including GPCRs on 21st-23rd September 2020. It is hoped that planned 2020 meetings can take place on similar dates in 2021.


Please check and our social media outlets (Twitter @RSC_BMCS, LinkedIn, Facebook and Instagram @RSCBMCS, YouTube) for any updates. It is our policy that 100% refunds be given to registered delegates. We would, however, ask for your patience for these to be processed. Thank you for your understanding.


For current information regarding the virus, please refer to the websites of the UK Government and Public Health England, or the World Health Organisation. 



Information from the Francis Crick Institute

At the Crick we are carefully monitoring the spread of novel coronavirus (2019-nCoV), and are putting measures in place to minimise the risk to anyone who is working at the Crick or visiting us.

Please read the information on our website which aligns with advice from Public Health England.

If you are feeling well and havenít visited one of the affected areas then we very much look forward to seeing you at the Kinase 2020 symposium on 1st June.


With more than 49 FDA-approved small molecules, the field of kinase inhibition continues to attract significant investment from the drug discovery and development community. The 9th RSC/SCI symposium on kinases will encompass plenary lectures on emergent topics and case studies of ongoing programmes as well as successful past programmes.


Programme Themes
This event will bring together industrial and academic experts representing many of the leading institutions in kinase drug discovery, to discuss a selection of new and emerging topics within the fields of kinase therapeutics for oncology and non-oncology therapies, and foster discussions within the wider industry through networking events such as poster sessions and industrial exhibitions.


Who should attend?
This event is aimed at all scientists interested in furthering their knowledge of kinases. It will also have wider appeal to members of the drug discovery community eager to understand how enzyme inhibitor programmes are approached and executed across the pharmaceutical industry. 


Call for Poster Abstracts

Abstracts are invited for poster presentation. Posters will be displayed throughout the meeting, and a dedicated poster session. There will also be an option for a flash oral presentation (two minutes, single slide).


The closing date is 21st May 2021.  Please download an abstract template here.


Programme (provisional)


Monday, 5th July 2021


Registration and refreshments


Opening remarks

Pascal Savy, Charles River, UK and Chairman of the Organising Committee


The shape-shifting protein kinases

Peter Parker, The Francis Crick Institute, UK


Application of FragLites to druggability and hit finding
Mike Waring, Newcastle University, UK


Refreshments, exhibition and posters



Session chair:  Nadia Ahmad, Charles River, UK


Fragment-based discovery of small molecule MRCK inhibitors

Mairi Sime, Beatson Drug Discovery Unit, UK


Fragment-derived, selective and orally-active inhibitors of DYRK1A and DYRK1B
Lee Walmsley, Vernalis Research, UK


Flash poster presentations (session 1)


Lunch, exhibition and posters



Session chair: Mihiro Sunose, Sygnature Discovery, UK


Discovery of AZD8154, a dual PI3Kγδ inhibitor, as an inhaled treatment for asthma

Matthew Perry, AstraZeneca, SE


Targeting diversity to define inhaled drug-like properties in atypical lipid kinase inhibitors

Heather Hobbs, GlaxoSmithKline, UK



Refreshments, exhibition and posters


Session chair:  John Cumming, F Hoffmann-La Roche, CH


Highly selective DDR1 Inhibitors from efficient screening and structure-guided design

Bernd Kuhn, F Hoffmann-La Roche, CH


Protein degradation of kinases with PROTACs: a route to differentiated medicines?

John Harling, GlaxoSmithKline, UK


Late breaker presentation (slot 1)

Speaker to be confirmed


Drinks and canapťs networking reception




Tuesday, 6th July


Session chair:  John Harris, CJH Consultants, UK


Design and evaluation of novel heterocyclic cysteine targeting covalent warheads and their application in identification of selective irreversible kinase inhibitors
Kirsten McAulay, Beatson Drug Discovery Unit, UK


The Meisenheimer complex in drug discovery: Reversible covalent inhibition of PLK1
Campbell McInnes, University of South Carolina, US


Refreshments, exhibition and posters



Session chair:  Douglas Williamson, Vernalis Research, UK


Targeting kinases for the treatment of neurodegeneration

Steve Andrews, ALBORADA Drug Discovery Institute, UK


X-ray structures and feasibility assessment of CLK2 inhibitors for Phelan McDermid syndrome
Andreas Lerchner, Novartis, CH


Discovery of potent TTBK1 inhibitors that lower tau phosphorylation in vivo for the treatment of Alzheimerís disease

Toma Halkina, Biogen, US


Flash poster presentations (session 2)


Lunch, exhibition and posters



Session chair:  Richard Ward, AstraZeneca, UK

13.55Poster prize-giving
14.00Exploiting the kinase conformational repertoire for allosteric regulation of IRE1α kinase-endoribonuclease

Ian Collins, The Institute of Cancer Research, UK

14.35Structure-based design of selective CaMK1 inhibitors

Sam Butterworth, The University of Manchester, UK


Structure-based drug design of selective WEE1 inhibitors
Tom Pesnot, Concept Life Sciences, UK


Closing remarks
Name, affiliation



Registration, Fees and Bursaries

Registration is not yet open, and fees will include Monday evening's drinks reception.


Early rates for payments received by 2nd April
£270 RSC or SCI member*
£335 Non-member
£130 RSC or SCI student** member
£155 Student** non-member

Standard rates for payments received between 3rd April and 2nd June
£335 RSC or SCI member*
£400 Non-member
£165 RSC or SCI student** member
£190 Student** non-member

Late rates for payments received from 3rd June onwards
£50 Late payment fee to be added to the above standard rates


*   Member is paid-up member of the RSC or SCI.
**  Student is undergraduate or post-graduate, not post-doc, and does not apply to students in paid employment.

Discounted rates are available for RSC and SCI student members, and some student bursaries are also available.  The closing date is 19th May 2021.   Please download an application form here.


Cancellation Policy

In the event of cancellation by 22nd June 2021, 80% of the fee paid will be refunded. Cancellations must be received in writing. Refunds will not be possible after that date although substitutions are possible at any time. In the unlikely event of cancellation of the meeting, fees paid will be refunded in full.


There will be a relevant trade exhibition and the charge is £990. This rate includes:

- stand space measuring 3 m wide x 2 m deep

- trestle table measuring 1.8 m wide x .8 m deep

- access to electricity and wi-fi

- inclusion of a promotional slide to be played in rotation on the main screen during breaks
- logo acknowledgement in the delegate handbook

- one full delegate with all catering.


Delegate pack inserts may be booked at £250 - no more than two sheets of A4 fixed together.



We are grateful to our confirmed sponsors







We are grateful to our supporters below



Venue and Travel

Address:  The Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK


Centrally located adjacent to Kingís Cross St Pancras railway station, the Institute is readily accessible by public transport.


Venue location weblink



A number of bedrooms will be held (via InCorporate Venues) at the Travelodge Kings Cross Royal Scot and the Travelodge Central Euston.  Guide prices from 2020 are below - exact rates to be confirmed next year.


Kings Cross Royal Scot, WC1X 9DT
£50.70    Sunday, 31st May per room + £6.30 per person for breakfast
£86.75    Monday, 1st June per room + £6.30 per person for breakfast

Release date: 3rd April 2020 at midday

Travelodge Central Euston, NW1 1DJ

£81.60    Sunday, 31st May per room + £6.30 per person for breakfast
£153.70    Monday, 1st June per room + £6.30 per person for breakfast

Release date: 3rd April 2020 at midday
If you require additional nights, please book the available night (Monday 1st) on
this link and add a note to your booking to request any extra nights. InCorporate Venues will add these at the best flexible rate and will send you a consolidated booking confirmation.


Organising Committee

John CummingF Hoffmann-La Roche
John HarrisCJH Consultants
Pascal Savy (chair)Charles River
Mihiro SunoseSygnature Discovery
Richard WardAstraZeneca
Douglas Williamson (treasurer)Vernalis Research


Secretariat Contact

Maggi Churchouse Events, 3 East Barn, Market Weston Road, Thelnetham, Diss IP22 1JJ, UK

E-mail Maggi Churchouse

Telephone: +44 (0)1359 221004


Registration is not yet open


Link to return to the RSC BMCS index page